Human CellExp™ CEACAM1/CD66a, Extracellular Domain (ED), Human Recombinant

CEACAM1, also known as biliary glycoprotein I (BGP I) or CD66a, is an extensively studied cell surface molecule with established functions in multiple cancer types, as well as in various compartments of the immune system. The highly glycosylated CEACAM1 contains a 35-428 amino acid extracellular domain (ECD) which includes one N-terminal V-type Ig-like domain, followed by three C2-type Ig-like domains. CEACAM1 is a surface glycoprotein expressed on various blood cells, epithelial cells, and vascular cells. It was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic binding, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.